Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency.

Muller AF, Leebeek FW, Janssen JA, Lamberts SW, Hofland L, van der Lely AJ

The Journal of clinical endocrinology and metabolism1 Nov 2001Cited by 14 (Europe PMC)

PMID11701672DOI10.1210/jcem.86.11.7987PepBankPUB-11701672

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In healthy nonobese men, pegvisomant alone reduced free IGF-I from 0.86 +/- 0.23 to 0.46 +/- 0.23 ng/ml.
In plain wordsIn healthy nonobese men, pegvisomant alone reduced free IGF-I from baseline.
Peptide
Pegvisomant
Outcome
DecreaseFree IGF-I with pegvisomant alone
Study
n: not reported in source
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Serum free IGF-I
0.86 ng/ml
pegvisomant alone, before (+/- 0.23)
Serum free IGF-I
0.46 ng/ml
pegvisomant alone, after (+/- 0.23)
Source sentences
Summary
Three days of fasting as well as pegvisomant alone decreased serum free IGF-I levels (1.0 +/- 0.15 vs. 0.31 +/- 0.05 ng/ml and 0.86 +/- 0.23 vs. 0.46 +/- 0.23 ng/ml, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated in healthy nonobese males the effect of the GH receptor antagonist pegvisomant in different metabolic conditions.
Summary · context
We compared the effect of pegvisomant with that of placebo before and after 3 d of fasting.
Summary · context
In addition, we investigated the effect of pegvisomant under normal, i.e. fed, conditions.
Report a problemFND-1170167201
02HumanNon-randomized trialEfficacy outcome
In healthy nonobese men, pegvisomant did not further reduce free IGF-I compared with fasting alone.
In plain wordsIn healthy nonobese men, pegvisomant did not further reduce free IGF-I compared with fasting alone.
Peptide
Pegvisomant
Outcome
No significant changeAdditional free IGF-I decline during fasting
Study
n: not reported in source
Comparator
Fasting alone
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Serum free IGF-I
1 ng/ml
fasting alone, before (+/- 0.15)
Serum free IGF-I
0.31 ng/ml
fasting alone, after (+/- 0.05)
Serum free IGF-I
1 ng/ml
fasting with pegvisomant, before (+/- 0.15)
Serum free IGF-I
0.31 ng/ml
fasting with pegvisomant, after (+/- 0.07)
Source sentences
Summary
Treatment with pegvisomant had no additional influence on the decline of free IGF-I induced by fasting.
5 context sentences(design, population, supporting numbers)
Summary · context
We investigated in healthy nonobese males the effect of the GH receptor antagonist pegvisomant in different metabolic conditions.
Summary · context
We compared the effect of pegvisomant with that of placebo before and after 3 d of fasting.
Summary · context
In addition, we investigated the effect of pegvisomant under normal, i.e. fed, conditions.
Summary · context
Three days of fasting as well as pegvisomant alone decreased serum free IGF-I levels (1.0 +/- 0.15 vs. 0.31 +/- 0.05 ng/ml and 0.86 +/- 0.23 vs. 0.46 +/- 0.23 ng/ml, respectively).
Summary · context
Fasting in combination with pegvisomant also decreased serum free IGF-I levels (1.0 +/- 0.15 vs. 0.31 +/- 0.07 ng/ml).
Report a problemFND-1170167202
03HumanNon-randomized trialEfficacy outcome
In healthy nonobese men, pegvisomant alone did not influence insulin sensitivity.
In plain wordsIn healthy nonobese men, pegvisomant alone did not influence insulin sensitivity.
Peptide
Pegvisomant
Outcome
No significant changeInsulin sensitivity with pegvisomant alone
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Pegvisomant alone had no influence on insulin sensitivity.
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated in healthy nonobese males the effect of the GH receptor antagonist pegvisomant in different metabolic conditions.
Summary · context
We compared the effect of pegvisomant with that of placebo before and after 3 d of fasting.
Summary · context
In addition, we investigated the effect of pegvisomant under normal, i.e. fed, conditions.
Report a problemFND-1170167203
04HumanNon-randomized trialEfficacy outcome
In healthy nonobese men, fasting with pegvisomant produced an insulin sensitivity increase comparable to fasting alone.
In plain wordsIn healthy nonobese men, insulin sensitivity increased similarly with fasting plus pegvisomant and fasting alone.
Peptide
Pegvisomant
Outcome
Direction not reportedInsulin sensitivity during fasting
Study
n: not reported in source
Comparator
Fasting alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
The increase in insulin sensitivity induced by fasting was comparable to the increase in insulin sensitivity induced by fasting combined with pegvisomant.
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated in healthy nonobese males the effect of the GH receptor antagonist pegvisomant in different metabolic conditions.
Summary · context
We compared the effect of pegvisomant with that of placebo before and after 3 d of fasting.
Summary · context
In addition, we investigated the effect of pegvisomant under normal, i.e. fed, conditions.
Report a problemFND-1170167204
05HumanNon-randomized trialEfficacy outcome
In healthy nonobese men, pegvisomant alone significantly increased triglycerides from 1.0 +/- 0.2 to 1.6 +/- 0.4 mmol/liter.
In plain wordsIn healthy nonobese men, pegvisomant alone increased triglycerides from baseline.
Peptide
Pegvisomant
Outcome
IncreaseSerum triglycerides
Study
n: not reported in source
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Measurements
Serum triglycerides
1 mmol/liter
pegvisomant alone, first value (+/- 0.2)
Serum triglycerides
1.6 mmol/liter
pegvisomant alone, second value (+/- 0.4)
Source sentences
Summary
Among serum lipid concentrations, only serum triglycerides increased significantly as a result of pegvisomant alone (1.0 +/- 0.2 vs. 1.6 +/- 0.4 mmol/liter).
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated in healthy nonobese males the effect of the GH receptor antagonist pegvisomant in different metabolic conditions.
Summary · context
We compared the effect of pegvisomant with that of placebo before and after 3 d of fasting.
Summary · context
In addition, we investigated the effect of pegvisomant under normal, i.e. fed, conditions.
Report a problemFND-1170167205
06HumanNon-randomized trialEfficacy outcome
In healthy nonobese men, serum lipids other than triglycerides did not significantly increase with pegvisomant alone.
In plain wordsIn healthy nonobese men, other serum lipids did not significantly increase with pegvisomant alone.
Peptide
Pegvisomant
Outcome
No significant changeOther serum lipids
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Among serum lipid concentrations, only serum triglycerides increased significantly as a result of pegvisomant alone (1.0 +/- 0.2 vs. 1.6 +/- 0.4 mmol/liter).
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated in healthy nonobese males the effect of the GH receptor antagonist pegvisomant in different metabolic conditions.
Summary · context
We compared the effect of pegvisomant with that of placebo before and after 3 d of fasting.
Summary · context
In addition, we investigated the effect of pegvisomant under normal, i.e. fed, conditions.
Report a problemFND-1170167206
07HumanNon-randomized trialEfficacy outcome
In healthy nonobese men, pegvisomant alone significantly reduced von Willebrand factor antigen from 1.1 +/- 0.07 to 0.8 +/- 0.06 U/ml.
In plain wordsIn healthy nonobese men, pegvisomant alone reduced von Willebrand factor antigen from baseline.
Peptide
Pegvisomant
Outcome
Decreasevon Willebrand factor antigen
Study
n: not reported in source
Comparator
Baseline
Outcome group
Cardiovascular Risk Markers · Cardiovascular
Studied dose
Dose not stated
Measurements
von Willebrand factor antigen
1.1 U/ml
pegvisomant alone, first value (+/- 0.07)
von Willebrand factor antigen
0.8 U/ml
pegvisomant alone, second value (+/- 0.06)
Source sentences
Summary
von Willebrand factor antigen levels declined significantly under the influence of pegvisomant alone (1.1 +/- 0.07 vs. 0.8 +/- 0.06 U/ml).
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated in healthy nonobese males the effect of the GH receptor antagonist pegvisomant in different metabolic conditions.
Summary · context
We compared the effect of pegvisomant with that of placebo before and after 3 d of fasting.
Summary · context
In addition, we investigated the effect of pegvisomant under normal, i.e. fed, conditions.
Report a problemFND-1170167207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.